Gilead Sciences, Inc. $GILD Stock: State Street Corp Lowers Stake

Gilead Sciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street trimmed its Gilead stake by 0.4%, selling 261,585 shares in the third quarter. It still held about 60.95 million shares, or 4.91% of the company.
  • Gilead’s latest quarterly results beat expectations: EPS was $2.55 versus a $2.19 consensus, while revenue rose 6.8% year over year to $8.30 billion. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $171.63.
  • Company insiders sold 237,709 shares worth about $39.8 million over the last quarter. Gilead also announced a quarterly dividend of $0.82 per share.
  • MarketBeat previews the top five stocks to own by December 1st.

State Street Corp lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 0.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 60,954,967 shares of the biopharmaceutical company's stock after selling 261,585 shares during the quarter. State Street Corp owned 4.91% of Gilead Sciences worth $9,085,338,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc bought a new stake in Gilead Sciences in the 2nd quarter worth $1,316,606,000. Deutsche Bank AG bought a new stake in Gilead Sciences in the 2nd quarter worth $918,387,000. Jupiter Topco LLC bought a new stake in Gilead Sciences in the 2nd quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Gilead Sciences in the second quarter valued at about $398,905,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $170.55, for a total value of $4,775,400.00. Following the completion of the sale, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. This trade represents a 20.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the sale, the executive vice president directly owned 5,360 shares in the company, valued at approximately $879,629.60. The trade was a 38.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 237,709 shares of company stock worth $39,799,137. 0.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on GILD. Argus set a $190.00 price objective on shares of Gilead Sciences in a research note on Thursday, November 12th. Barclays increased their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock an "equal weight" rating in a report on Monday, November 16th. Morgan Stanley raised their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an "overweight" rating in a research note on Friday, October 30th. TD Cowen set a $175.00 price target on Gilead Sciences in a report on Wednesday. Finally, Truist Financial upped their price target on Gilead Sciences from $158.00 to $181.00 and gave the company a "buy" rating in a research report on Friday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and an average target price of $171.63.

Read Our Latest Analysis on Gilead Sciences

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $166.33 on Friday. The stock has a market cap of $206.30 billion, a P/E ratio of -52.64 and a beta of 0.35. The firm's fifty day simple moving average is $157.26 and its 200 day simple moving average is $142.46. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the firm earned $2.47 EPS. The company's quarterly revenue was up 6.8% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences's payout ratio is presently -103.80%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Recommended Stories

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gilead Sciences Right Now?

Before you consider Gilead Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.

While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines